Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 3/20 | 0.65 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | DRD3 | P35462 | 4/20 | 0.62 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.62 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.62 |
| ▸ | HTR2A | P28223 | 3/20 | 0.62 |
| ▸ | HRH1 | P35367 | 3/20 | 0.62 |
| ▸ | HTR2B | P41595 | 3/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.62 |
| ▸ | DRD2 | P14416 | 3/20 | 0.62 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.62 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.62 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.62 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.62 |
| ▸ | DRD4 | P21917 | 1/20 | 0.62 |
| ▸ | HRH2 | P25021 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10367443 | 0.94 | DRD3 (0.60) | OPRD1OPRM1KMT2AMEN1DRD3 | |
| SCHEMBL1405261 | 0.91 | DRD3 (0.76) | OPRD1OPRM1KMT2AMEN1DRD3 | |
| SCHEMBL20039912 | 0.91 | OPRD1 (0.64) | OPRD1OPRM1KMT2AMEN1DRD3 | |
| SCHEMBL13845055 | 0.91 | DRD3 (0.76) | OPRD1OPRM1KMT2AMEN1DRD3 | |
| SCHEMBL6618656 | 0.90 | DRD3 (0.63) | OPRD1OPRM1KMT2AMEN1DRD3 | |
| Hydrochloric Acid SCHEMBL5113093 | 0.89 | DRD3 (0.74) | OPRD1OPRM1KMT2AMEN1DRD3 | |
| SCHEMBL6617567 | 0.88 | DRD2 (0.63) | OPRD1OPRM1KMT2AMEN1DRD3 | |
| Hydrochloric Acid SCHEMBL6475984 | 0.88 | DRD3 (0.73) | OPRD1OPRM1KMT2AMEN1DRD3 | |
| SCHEMBL6617019 | 0.87 | DRD2 (0.62) | OPRD1OPRM1KMT2AMEN1DRD3 | |
| Decloxizine SCHEMBL2110441 | 0.84 | HRH1 (0.85) | OPRD1OPRM1KMT2AMEN1DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117720457-A | Manidipine hydrochloride process impurity m-nifedipine and preparation method and application thereof | 成都大学 | 2024-03-19 | — | — | CN | claimed |
| CN-103351362-A | Preparation method of manidipine intermediate 2-(4-diphenylmethyl piperazinyl)ethyl acetoacetate | ZHANGJIAGANG WEISHENG BIOLOG PHARCEUTICAL CO LTD | 2013-10-16 | — | — | CN | claimed |
| CN-103214434-A | Improved method of 1-diphenylmethyl-4-(2-hydroxyethyl) piperazine synthesis technology | ZHANGJIAGANG WEISHENG BIOLOG MEDICAL CO LTD | 2013-07-24 | — | — | CN | claimed |
| EP-1157016-B1 | A PROCESS FOR THE PREPARATION OF 2- 2- 4-(DIPHENYLMETHYL)-1-PIPERAZINYL]ETHOXY ACETIC ACID COMPOUNDS OR SALTS THEREOF | GEA FARMACEUTISK FABRIK AS (DK) | 2003-10-08 | — | — | EP | claimed |
| EP-1157016-A1 | A PROCESS FOR THE PREPARATION OF 2- 2- 4-(DIPHENYLMETHYL)-1-PIPERAZINYL]ETHOXY ACETIC ACID COMPOUNDS OR SALTS THEREOF | A/S GEA Farmaceutisk Fabrik (DK) | 2001-11-28 | — | — | EP | claimed |
| WO-2000052000-A1 | A PROCESS FOR THE PREPARATION OF 2-{2-[4-(DIPHENYLMETHYL)-1-PIPERAZINYL]ETHOXY}ACETIC ACID COMPOUNDS OR SALTS THEREOF | A/S GEA FARMACEUTISK FABRIK (DK) | 2000-09-08 | — | — | WO | claimed |
| US-5644059-A | REACTION OF KETONE WITH ACRYLAMIDE AND AMMONIA OR AMMONIUM SALT | FUJIREBIO INC. (JP) | 1997-07-01 | — | — | US | claimed |
| EP-0488345-A1 | 1,4-Dihydropyridine derivatives and methods of producing the same | FUJIREBIO INC. (JP) | 1992-06-03 | — | — | EP | claimed |
| JP-9278751-A | — | — | None | — | — | JP | disclosed |
| CN-117720457-A | Manidipine hydrochloride process impurity m-nifedipine and preparation method and application thereof | 成都大学 | 2024-03-19 | — | — | CN | disclosed |
| CN-115572253-A | Synthesis process of manidipine hydrochloride raw material medicine | 许昌恒生制药有限公司 | 2023-01-06 | — | — | CN | disclosed |
| CN-115403512-A | Method for controlling key impurities of manidipine hydrochloride raw material medicine | 许昌恒生制药有限公司 | 2022-11-29 | — | — | CN | disclosed |
| US-20220193020-A1 | Pharmaceutical Composition Comprising Trimebutine or Pharmaceutically Acceptable Salt Thereof as an Active Ingredient For Prevention or Treatment of Cancer | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2022-06-23 | — | — | US | disclosed |
| CN-106518806-A | Preparation method for manidipine intermediate 2-(4-diphenylmethyl piperazine)ethyl acetoacetate | 张家港威胜生物医药有限公司 | 2017-03-22 | — | — | CN | disclosed |
| EP-0094159-B1 | DIHYDROPYRIDINE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1990-03-14 | — | — | EP | disclosed |
| US-4892875-A | HYPOTENSIVE, RENAL VASODILATION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1990-01-09 | — | — | US | disclosed |
| WO-1988002750-A1 | 1,4-DIHYDROPYRIDINE | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1988-04-21 | — | — | WO | disclosed |
| US-4603135-A | HYPOTENSIVE AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1986-07-29 | — | — | US | disclosed |
| EP-0138505-A2 | Dihydropyridine derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1985-04-24 | — | — | EP | disclosed |
| EP-0094159-A1 | Dihydropyridine derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1983-11-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220193020-A1 | Pharmaceutical Composition Comprising Trimebutine or Pharmaceutically Acceptable Salt Thereof as an Active Ingredient For Prevention or Treatment of Cancer | TRIM59, TRIM24, WASHC5 | OPRD1 3894/4885OPRM1 4182/4885KMT2A 1171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.